TP53 and acute myeloid leukemia: Nonetheless, the observed overall composite remission rate is similar to the 55% CR + CRi rate observed in patients with mutant TP53 who were treated with venetoclax plus azacitidine (12), and the median OS in the present trial (7.6 months) was similar to that of other leading investigational therapies for TP53-mutated AML.